WO2002000170A3 - Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic - Google Patents
Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic Download PDFInfo
- Publication number
- WO2002000170A3 WO2002000170A3 PCT/US2001/020444 US0120444W WO0200170A3 WO 2002000170 A3 WO2002000170 A3 WO 2002000170A3 US 0120444 W US0120444 W US 0120444W WO 0200170 A3 WO0200170 A3 WO 0200170A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- patients
- radiosensitizers
- targeted delivery
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002504953A JP2004501171A (ja) | 2000-06-28 | 2001-06-28 | A)臓器が移植された患者における活性化されたリンパ球への、b)放射線療法を受ける患者における、癌細胞への放射線増感剤としての、c)癌の診断および治療における薬物担体としてのビタミン結合タンパク質中の、細胞毒の標的指向型送達 |
CA002414401A CA2414401A1 (fr) | 2000-06-28 | 2001-06-28 | Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic |
IL15358601A IL153586A0 (en) | 2000-06-28 | 2001-06-28 | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
US10/311,302 US20040028686A1 (en) | 2001-06-28 | 2001-06-28 | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplated organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
AU2001271525A AU2001271525A1 (en) | 2000-06-28 | 2001-06-28 | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
EP01950547A EP1305051A4 (fr) | 2000-06-28 | 2001-06-28 | Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medi |
US11/952,181 US20080095802A1 (en) | 2000-06-28 | 2007-12-07 | Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21442700P | 2000-06-28 | 2000-06-28 | |
US21438900P | 2000-06-28 | 2000-06-28 | |
US21438800P | 2000-06-28 | 2000-06-28 | |
US60/214,388 | 2000-06-28 | ||
US60/214,389 | 2000-06-28 | ||
US60/214,427 | 2000-06-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/952,181 Continuation US20080095802A1 (en) | 2000-06-28 | 2007-12-07 | Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002000170A2 WO2002000170A2 (fr) | 2002-01-03 |
WO2002000170A3 true WO2002000170A3 (fr) | 2002-08-08 |
Family
ID=27395985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/020444 WO2002000170A2 (fr) | 2000-06-28 | 2001-06-28 | Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1305051A4 (fr) |
JP (1) | JP2004501171A (fr) |
AU (1) | AU2001271525A1 (fr) |
CA (1) | CA2414401A1 (fr) |
IL (1) | IL153586A0 (fr) |
WO (1) | WO2002000170A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094271A1 (fr) | 2001-05-15 | 2002-11-28 | Faulk Pharmaceuticals, Inc. | Administration ciblee de composes bioactifs pour le traitement du cancer |
CA2447335C (fr) | 2001-05-15 | 2011-01-04 | Faulk Pharmaceuticals, Inc. | Administration ciblee de medicaments pour le traitement d'infections virales |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5000935A (en) * | 1985-08-02 | 1991-03-19 | Faulk Ward P | Treatment method utilizing transferrin-radioiodine conjugate |
US5108987A (en) * | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
US6150341A (en) * | 1998-06-12 | 2000-11-21 | Biotch Australia Pty Limited | Vitamin B12 derivatives and methods for their preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4489710A (en) * | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
US5208021A (en) * | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
US5792458A (en) * | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
CA2016584C (fr) * | 1989-05-17 | 1999-06-29 | Robert S. Greenfield | Conjugats d'anthracycline ayant un nouvel adapteur et methodes de production |
-
2001
- 2001-06-28 JP JP2002504953A patent/JP2004501171A/ja active Pending
- 2001-06-28 CA CA002414401A patent/CA2414401A1/fr not_active Abandoned
- 2001-06-28 AU AU2001271525A patent/AU2001271525A1/en not_active Abandoned
- 2001-06-28 EP EP01950547A patent/EP1305051A4/fr not_active Withdrawn
- 2001-06-28 IL IL15358601A patent/IL153586A0/xx unknown
- 2001-06-28 WO PCT/US2001/020444 patent/WO2002000170A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108987A (en) * | 1982-02-25 | 1992-04-28 | Faulk Ward P | Conjugates of proteins with anti-tumor agents |
US5000935A (en) * | 1985-08-02 | 1991-03-19 | Faulk Ward P | Treatment method utilizing transferrin-radioiodine conjugate |
US6150341A (en) * | 1998-06-12 | 2000-11-21 | Biotch Australia Pty Limited | Vitamin B12 derivatives and methods for their preparation |
Non-Patent Citations (2)
Title |
---|
KISHIMOTO, T. ET AL.: "Receptors for transferrin and transcobalamin II display segregated distribution on microvilli of leukemia L1210 cells", BIOCHEM. BIPHYS. RES. COMMUN., vol. 146, no. 3, 14 August 1987 (1987-08-14), pages 1102 - 1108, XP002950815 * |
WOODWARD ET AL.: "Enhanced allograft survival via simultaneous blockade of transferrin receptor and interleukin-2 receptor", TRANSPLANTATION, vol. 68, no. 9, 15 November 1999 (1999-11-15), pages 1369 - 1376, XP002950816 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002000170A2 (fr) | 2002-01-03 |
IL153586A0 (en) | 2003-07-06 |
EP1305051A4 (fr) | 2007-01-10 |
AU2001271525A1 (en) | 2002-01-08 |
CA2414401A1 (fr) | 2002-01-03 |
EP1305051A2 (fr) | 2003-05-02 |
JP2004501171A (ja) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2301531A3 (fr) | Combinaisons et modes d'administration d'agents therapeutiques et traitement combine | |
WO2005044365A3 (fr) | Therapie par l'intermediaire d'une administration ciblee de particules a nano-echelle | |
EP2332542A3 (fr) | Utilisation de composes renfermant du methylol pour la fabrication d'un medicament pour traiter des tumeurs | |
EP1586338A3 (fr) | Utilisation d'antioxydants pour la prévention d'oxydation et la réduction de la dégradation des principes actifs dans les articles médicaux libérant des principes actifs | |
EP2548880A3 (fr) | Compositions pour augmenter l'activité de la télomérase | |
AR042795A1 (es) | Fluidos de dialisis biocompatibles que contienen icodextrinas | |
WO2003084470A3 (fr) | Compositions et procedes pour apport biologique cible de porteurs moleculaires | |
SG49841A1 (en) | Keratinocyte growth factor (kfg) for its use in method of therapeutic treatment for the human or animal body | |
WO2020222866A1 (fr) | Utilisation thérapeutique et prophylactique de mitochondries et d'agents mitochondriaux combinés | |
WO2005113720A3 (fr) | Technique pour la conception de medicaments anticancereux specifiques au patient | |
EP1706145A4 (fr) | Autoanticorps utilises comme excipients avec des composes pharmaceutiques utilises dans l'imagerie tumorale et le traitement du cancer | |
WO2002102311A3 (fr) | Compositions pharmaceutique et de diagnostic contenant des nanoparticules utiles pour le traitement de tissus et de cellules cibles | |
RU2335539C2 (ru) | Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации | |
WO2002000170A3 (fr) | Diffusion ciblee de medicaments cytotoxiques a) a des lymphocytes actives chez des patients porteurs d'organes transplantes, b) comme radiosensibiliseurs des cellules cancereuses chez des patients soumis a une radiotherapie et c) dans des proteines de liaison a des vitamines comme vecteurs de medicament dans le diagnostic | |
EP1226822A3 (fr) | Promoteurs de la production de l'oxyde d'azote et de la NO synthéthase, compositions cosmétiques et pharmaceutiques les contenant | |
HUP0401188A2 (hu) | Hiperelágazásos amilopektin sebészeti, gyógyító vagy diagnosztikai eljárásokban emlősöknél való alkalmazásra, különösen plazmatérfogat-növelőként | |
WO2002094199A3 (fr) | Procede d'augmentation des niveaux d'anticorps anti-neugc dans le sang | |
DE602005026510D1 (en) | Anthracyclinderivate | |
MD2211G2 (ro) | Remediu pentru tratamentul afecţiunilor periodonţiului | |
WO2005028608A3 (fr) | Processeur de cellules servant a traiter des maladies | |
CN114848836B (zh) | 一种偶联物及其在治疗内耳疾病上的应用 | |
Kolb et al. | Dose rate and fractionation of total body irradiation in dogs: short and long term effects | |
Kasakura | Great contributions of E. Donnall Thomas to the development of clinical applications of bone marrow transplantation, leading to the 1990 Nobel Prize in Medicine/Physiology | |
RU2005127503A (ru) | Способ лечения рецидива рака молочной железы | |
Muramatsu et al. | Treatment strategy for recurrent and refractory epithelial ovarian cancer: efficacy of high-dose chemotherapy with hematopoietic stem cell transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 153586 Country of ref document: IL Ref document number: 2414401 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10311302 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001271525 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001950547 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001950547 Country of ref document: EP |